A Phase I Dose-escalation Study to Assess the Safety of AFM11 (CD19 x CD3 TandAb®) in Patients With Relapsed or Refractory Adult B-precursor Acute Lymphoblastic Leukemia

Next Previous
Trial Profile

A Phase I Dose-escalation Study to Assess the Safety of AFM11 (CD19 x CD3 TandAb®) in Patients With Relapsed or Refractory Adult B-precursor Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs AFM 11 (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Acronyms AFM11-102
  • Sponsors Affimed Therapeutics

    • Most Recent Events

    • 20 Mar 2018 According to an Affimed Therapeutics media release, company is recruiting patients for the fifth cohort of the study.
    • 01 Aug 2017 According to an Affimed Therapeutics media release, patients are currently being recruited into the fourth dose cohort of this trial.
    • 30 Mar 2017 According to an Affimed Therapeutics media release, company expects providing a progress update of this trial in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top